AFF4 Loss Compromises Osteogenesis of Orofacial Mesenchymal Stem Cells During Alveolar Bone Repair via AMPK‐Mediated Mitophagy Li Zhu, Shuo Chen, Guowen Luo, Tingyue Zhang, Hengyi Lin, Yiling Chen, Chenchen Zhou, Shujuan Zou Abstract Repair of maxillofacial bone defects presents significant clinical challenges. Orofacial mesenchymal stem cells (OMSCs) mediate maxillofacial bone repair, while the molecular mechanisms governing osteogenic commitment of OMSCs remain incompletely understood. Here, we investigate the function of AF4/FMR2 family member 4 (AFF4) in OMSCs osteogenesis and maxillofacial bone healing. By using a tamoxifen‐inducible Aff4 knockout mouse model, we demonstrate that AFF4 depletion significantly delays the alveolar bone repair post‐tooth extraction. OMSCs of Aff4 knockout mice exhibit decreased expression of osteogenic markers (RUNX2, ALPL, OSX, COL1A1) and reduced mineralization in vitro. Mechanistically, AFF4 loss suppresses AMPK signalling and downstream mitophagy, manifested by reduced Parkin translocation and LC3B recruitment to mitochondria, and impaired mitophagosome‐lysosome fusion. Notably, the rescue of mitophagy and the osteogenic capacity of Aff4‐deficient OMSCs by AICAR (an AMPK activator) was abolished by Compound C (an AMPK inhibitor). Collectively, our findings establish the critical role of AFF4 in maxillofacial bone regeneration and demonstrate that it functions through the AMPK‐mitophagy axis in OMSCs. This study provides a novel insight into the function of AFF4 in maxillofacial bone biology. Compromised alveolar socket healing following tooth extraction upon Aff4 knockout is caused by suppressed osteogenic capacity of orofacial mesenchymal stem cells, which results from defective AMPK‐mediated mitophagy.[CPR-9999-e70284-g007.webp] Introduction Maxillofacial bones are essential for mastication, speech and facial aesthetics []. Maxillofacial bone defects, caused by trauma, inflammation, or congenital anomalies, compromise patients' quality of life and impose challenges to clinical management []. Notably, maxillofacial bones differ from other skeletal bones in terms of embryonic origin and homeostatic mechanisms []. Orofacial mesenchymal stem cells (OMSCs), inherent stem cells residing in jaw bones, originate from ectodermal neural crest cells []. Given the intrinsic and niche‐specific variations, OMSCs exhibit unique properties compared to mesenchymal stem cells (MSCs) of long bones. Specifically, OMSCs exhibit superior proliferative, osteogenic and angiogenic potential [, ]. OMSCs are particularly promising for craniomaxillofacial defect repair due to their easier accessibility, reduced trauma and lower immunogenicity [, ]. Therefore, in‐depth exploration of the molecular regulatory mechanisms governing osteogenic differentiation of OMSCs is critical for developing novel therapeutic strategies for maxillofacial bone defect regeneration. AF4/FMR2 family member 4 (AFF4) works as the scaffold to assemble and stabilize super elongation complex (SEC) []. AFF4/SEC enables rapid transcriptional induction by releasing paused RNA polymerase II from the promoter‐proximal site []. Beyond its established roles in tumorigenesis [, , ] and HIV transactivation [, , , ], AFF4 has also been found to be implicated in bone biology over the past decade. Germline AFF4 missense mutations cause CHOPS syndrome, a developmental disorder in which skeletal involvement is universally observed [, ]. Additionally, AFF4 has been shown to regulate osteogenic commitment of several kinds of stem cells, including human MSCs, dental follicle cells and periodontal ligament stem cells (PDLSCs) [, ]. Nevertheless, the role of AFF4 in OMSCs‐mediated maxillofacial bone repair remains elusive. Mitophagy is an organelle‐specific autophagic process where autophagosomes engulf damaged mitochondria and then fuse with lysosomes for degradation. In canonical Parkin‐dependent mitophagy, E3 ubiquitin ligase Parkin translocates from the cytosol to mitochondria and is activated by PINK1 on the outer mitochondrial membrane. Activated Parkin ubiquitinates outer mitochondrial membrane proteins, which then recruit core autophagy machinery, ultimately leading to autophagosome formation and mitophagy initiation []. AMP‐activated protein kinase (AMPK), a known autophagy regulator [], has been shown to govern the early stage of Parkin‐mediated mitophagy. Specifically, AMPK phosphorylates Parkin on Ser108 through both ULK1‐dependent and ULK1‐independent mechanisms, causing its translocation to mitochondria and subsequent full activation by PINK1 [, , ]. A growing number of studies suggest AMPK signalling drives osteogenesis via mitophagy [, ]. Emerging evidence indicates that AFF4 regulates AMPK expression. Komori et al. reported that AFF4 regulates AMPKα2 transcription in the mouse hypothalamic neuronal cell line GT1‐7. Using luciferase assays, they demonstrated that AFF4 overexpression significantly increased AMPKα2 promoter activity compared with mock‐transfected controls []. Moreover, RNA‐seq analysis of human PDLSCs revealed downregulation of AMPKα2 and significant enrichment of mitophagy‐related pathways following siRNA‐mediated AFF4 knockdown []. Hence, we speculate that AFF4 functions during maxillofacial bone regeneration by regulating AMPK‐mediated mitophagy. To test our hypothesis, we generated a tamoxifen‐inducible Aff4 knockout mouse model to examine how AFF4 influences alveolar bone healing and the osteogenic potential of OMSCs. Our experiments demonstrate that AFF4 loss leads to compromised osteogenesis and defective alveolar bone repair. Mechanistically, AFF4 depletion suppresses the osteogenic capability of OMSCs, partially through the modulation of AMPK‐mediated mitophagy. Materials and Methods Mice Breeding and Surgery Aff4 fl/fl mice, with loxP sites inserted to flank exons 2 and 3 of the Aff4 gene, were produced by Biocytogen Pharmaceuticals (Beijing, China). We crossed CAG‐iCre male mice (GemPharmatech, Nanjing, China) and Aff4 fl/fl female mice to obtain CAG‐iCre; Aff4 fl/fl mice. Global Aff4 knockout was induced in 3‐week‐old CAG‐iCre; Aff4 fl/fl mice by daily intraperitoneal injection of tamoxifen (0.15 mg/g body weight; J60955.06; ThermoFisher) for three consecutive days. Aff4 fl/fl littermates injected with tamoxifen served as controls. One week after injection, an alveolar defect repair model was established by extracting the maxillary right first molar in CAG‐iCre; Aff4 fl/fl and Aff4 fl/fl male mice. Maxillae were harvested at 7, 14 and 21 days post‐tooth extraction for subsequent analysis. Animal experiments were conducted with ethical approval (WCHSIRB‐AT‐2025‐543). Microcomputed Tomography (Micro‐CT) Analysis Jaws from CAG‐iCre; Aff4 fl/fl mice and Aff4 fl/fl littermates were fixed with 4% paraformaldehyde for 24–48 h and kept in PBS until scanning. Scanning was performed with Venus Micro CT (PingSeng Scientific, China), followed by three‐dimensional volumetric reconstruction. The palatal root socket of the extracted first molar was defined as the region of interest. Thresholds were set to encompass all trabecular and cortical bone and were maintained consistently across all groups. Histological Staining The samples were processed into paraffin sections after fixation, decalcification and dehydration. The sections were deparaffinized and rehydrated before staining. Haematoxylin and Eosin (H&E), Alkaline phosphatase (ALP) and tartrate‐resistant acid phosphatase (TRAP) staining were performed using commercial kits (H&E: BL735A, Biosharp; TRAP/ALP: 294‐67001, Wako) following the manufacturer's instructions. For immunohistochemical (IHC) staining, VECTASTAIN ABC‐HRP Kit (PK‐4001, Vector Laboratories) and DAB peroxidase substrate kit (SK‐4100, Vector Laboratories) were utilized. Briefly, sections were immersed in sodium citrate buffer (P0083, Beyotime) at 100°C for 20 min for antigen retrieval, followed by incubation with 3% H2O2 (AR1108, Boster) for 30 min for endogenous peroxidase inhibition. Afterwards, samples were incubated with anti‐OSX antibody (HA722817, Huabio) overnight at 4°C, and then with biotinylated secondary antibody for 2 h at room temperature. Subsequently, the DAB kit was used to perform immunolabelling and the nuclei were stained with haematoxylin. Section images were captured with Tissue Slide Scanner VS120 (Olympus). OSX‐positive cells and TRAP‐positive cells within the extraction sockets were counted and quantified using FIJI software (ImageJ, National Institutes of Health). OMSCs Isolation and Osteogenic Induction OMSCs were extracted and cultured as previously reported [, , ]. Briefly, mandibles of 4‐week‐old male mice were dissected, cut into small pieces and digested enzymatically at 37°C for 1 h with collagenase I (3 mg/mL; BioFroxx) and dispase II (4 mg/mL; Solarbio). After passing through a 70‐μm cell strainer, the cells were centrifuged and resuspended in DMEM (Gibco) with 10% foetal bovine serum (FBS; Gibco) and 1% penicillin–streptomycin (Gibco). Cells were cultured in a humidified incubator (37°C, 5% CO2) with medium renewed every 2 days. Cells were passaged upon reaching 80% confluence to obtain passages 2–5 for subsequent experiments. To evaluate the proliferative capacity of OMSCs, the CCK‐8 kit (K1018, APExBIO) was utilized and absorbance at 405 nm was detected by SpectraMax iD3. l‐ascorbic acid (50 μg/mL; Psaitong), dexamethasone (10 nM; Solarbio) and β‐glycerolphosphate (8 mM; Psaitong) were added into culture medium for osteogenic induction. 5‐aminoimidazole‐4‐carboxamide ribonucleotide (AICAR; 100 μM; S1515, Beyotime) and Compound C (CC; 10 μM; B3252, APExBIO) were added to activate or inhibit AMPK signalling, respectively. Protein Extraction and Western Blot (WB) For WB analysis of maxillary bone tissue, total proteins were extracted from mice at 7 days post‐tamoxifen administration [], and at 7 and 14 days post‐surgery. For WB analysis of OMSCs, total cellular proteins were obtained after osteogenic induction for 5 days. RIPA buffer (P0013B, Beyotime) supplemented with 1% protease inhibitor cocktail (P1005, Beyotime) was used to extract proteins. Following SDS‐PAGE separation, proteins were electroblotted onto PVDF membranes (Millipore). After blocking for 2 h with bovine serum albumin (BSA, 5%, BioFroxx), the blots were incubated with primary antibodies (overnight, 4°C), and then with HRP‐conjugated secondary antibodies (2 h, room temperature). Bands detection was performed with ECL reagent (K1231, APExBIO) on a ChemiDoc system (Bio‐Rad). The optical density of each protein band was quantified using FIJI software and normalized to the corresponding ACTB loading controls. Primary and secondary antibodies used in this experiment were provided in Table . RNA Extraction and Quantitative Real‐Time Polymerase Chain Reaction (qRT‐PCR) Total RNA was isolated from OMSCs using TRIzol (Invitrogen), and its concentration was measured with a NanoDrop OneC spectrophotometer (Thermo Fisher Scientific). Reverse transcription was conducted using the PrimeScript FAST RT reagent kit with gDNA Eraser (RR092A; TaKaRa). Subsequently, qRT‐PCR was performed with TB Green Premix Ex Taq II FAST qPCR (CN830A; TaKaRa) on a Roche LightCycler 480 II system (Switzerland). The 2−ΔΔCt method was used to calculate relative mRNA levels of targeted genes, with Gapdh as the endogenous reference. The primers used were listed in Table . Alkaline Phosphatase (ALP) Staining and Alizarin Red Staining Cells were cultured in 48‐well plates and subjected to osteogenic induction. 4% paraformaldehyde was used for cell fixation for 15 min before staining. BCIP/NBT staining kit (C3206, Beyotime) was utilized for ALP staining after 7 days of induction. 1% Alizarin Red S solution (G1452, Solarbio) was used to stain calcified nodules after 14 days of osteogenic induction. Immunofluorescence (IF) Staining Cells were first treated with MitoTracker Red CMXRos (200 nM; M7512, Thermo Fisher Scientific) for 15 min to label mitochondria. Subsequently, the cells were fixed with paraformaldehyde (4%, 10 min), permeabilized with Triton X‐100 (0.25%, 10 min) and blocked with BSA (5%, 1 h). Immunolabelling was performed by incubation with primary antibodies (4°C, overnight) and then with secondary antibody (room temperature, 2 h). Antibodies used in this experiment included anti‐LC3B (R382687, ZENBIO), anti‐Parkin (HA722952, Huabio) and secondary antibody (Alexa Fluor 488; A‐11008, Thermo Fisher Scientific). Nuclei were counterstained with DAPI (C0065, Solarbio). Immunofluorescent images were captured with SpinSR microscope (Olympus). Transmission Electron Microscopy After mitophagy induction with carbonyl cyanide m‐chlorophenyl hydrazone (CCCP; 10 μM; HY‐100941, MedChemExpress) for 2 h, cells were harvested by trypsinization and centrifugation. Cell fixation was performed by initial fixation with 2.5% glutaraldehyde and secondary fixation with 1% osmium tetroxide. Mitophagy was detected using a transmission electron microscope (JEM‐1400FLASH, JEOL). Mitochondrial Analysis Cells were seeded in confocal dishes and cultured either with or without AICAR treatment. The Enhanced Mitochondrial Membrane Potential Assay Kit with JC‐1 (C2003S, Beyotime), MitoSOX Red (M36008, Invitrogen) and Reactive Oxygen Species Assay Kit (S0033S, Beyotime) were used as the manufacturer instructed. A combination of MitoTracker Green (C1048, Beyotime) and LysoTracker Red (C1046, Beyotime) was used to visualize mitochondria and lysosomes. After removal of residual fluorescence probes, the dishes were mounted and observed under a live cell imaging system (Olympus). For MitoSOX and cellular ROS staining, the mean fluorescence intensity was measured using FIJI software. For JC‐1 staining, the red/green fluorescence intensity ratio was calculated to evaluate mitochondrial membrane potential. Statistical Analysis All mice (n = 5 per group) underwent the same tooth extraction surgery. Micro‐CT and histological data were acquired and quantified by investigators blinded to group allocation. Micro‐CT analysis was performed with five mice per group, and histological staining was based on three randomly selected samples per group. All other experiments were performed with three independent biological replicates. All quantitative results are displayed as mean ± standard deviation (SD). Comparison between two groups was performed using Student's t‐test. One‐way ANOVA with Tukey's multiple comparisons test was applied for comparisons among multiple groups. A p‐value of less than 0.05 was defined as statistically significant. GraphPad Prism 10.0 was used for all statistical analyses. Results Aff4 Loss Leads to Delayed Alveolar Socket Healing Firstly, an alveolar bone repair model was established, and the expression pattern of AFF4 during the healing process in wild‐type mice was examined. WB analysis of maxillary bone tissue revealed that AFF4 protein levels were significantly higher at Days 7 and 14 than at Day 0, with a more prominent increase at Day 7 (Figure ). To clarify the role of AFF4 in alveolar bone repair, 3‐week‐old CAG‐iCre; Aff4 fl/fl (hereafter, KO) mice and Aff4 fl/fl (hereafter, WT) littermates were subjected to tamoxifen administration and subsequent tooth extraction procedure (Figure ). One week after tamoxifen induction, WB assays confirmed effective knockout of AFF4 (Figure ). Three weeks post‐induction, KO mice showed similar body size to the WT littermates (Figure ), and no significant difference in the gross morphology of the jaw bones was observed (Figure ). Micro‐CT analysis showed delayed alveolar bone healing of KO mice at all evaluated time points. At Day 21, the extraction sockets of WT mice were nearly filled with new bone, while KO mice showed reduced bone fill and a more irregular bone surface (Figure ). Due to the difficulty in delineating the extraction socket boundaries at Day 21, only samples collected at Days 7 and 14 were employed for subsequent analyses. Quantitative analysis of micro‐CT data demonstrated that at Days 7 and 14, bone volume fraction (BV/TV) and trabecular thickness (Tb.Th) of newly formed bone in extraction sockets were lower in KO mice than in WT mice, whereas trabecular number (Tb.N) and trabecular separation (Tb.Sp) did not differ significantly between the two groups (Figure ). Histological techniques were further employed to characterize socket healing at Days 7 and 14. Consistent with micro‐CT findings, Haematoxylin and Eosin (H&E) staining showed that bone newly formed in extraction sockets of KO mice was reduced compared to WT mice at Days 7 and 14 (Figure ). We further investigated osteogenic and osteoclastic activity during alveolar socket healing. Alkaline phosphatase (ALP) staining demonstrated that alkaline phosphatase activity in WT mice remained consistently high at Days 7 and 14. In contrast, KO mice exhibited significantly lower ALP activity at Day 7. Although ALP activity in KO mice increased slightly at Day 14 compared to Day 7, it remained lower than that of WT mice at both time points (Figure ). Immunohistochemistry staining showed that cells expressing OSX, the osteoblastic marker, were markedly more abundant in WT mice than in KO mice (Figure ). Tartrate‐resistant acid phosphatase (TRAP) staining, however, detected no significant group difference in osteoclastic activity on Day 7 or Day 14 (Figure ). Taken together, AFF4 expression is elevated during extraction socket healing and inducible Aff4 knockout compromises osteogenic activity and alveolar bone repair, whereas osteoclastic activity remains unaffected at the early healing stage. Aff4 Ablation Compromises Osteogenic Differentiation of OMSCs Considering OMSCs are the key drivers of maxillofacial defect healing [], we further investigated whether AFF4 ablation affects osteogenic differentiation of these niche‐specific stem cells. OMSCs of WT and KO mice were isolated from mandibles via enzyme digestion (Figure ). Those OMSCs expressed CD44 and CD90, the MSC surface markers (Figure ). AFF4 deletion was confirmed by significantly reduced mRNA and protein levels using qRT‐PCR and WB (Figure ). Cell proliferation capacity was not significantly altered by AFF4 deficiency, as determined by CCK‐8 assays (Figure ). After osteogenic induction, OMSCs of KO mice expressed fewer osteogenic markers, including RUNX2, ALPL, OSX and COL1A1 (Figure ). Besides, ALP activity and calcium nodule deposition in KO OMSCs were also reduced compared to those of WT OMSCs (Figure ). Overall, these observations reveal that loss of Aff4 inhibits the osteogenic commitment of mouse OMSCs. Aff4 Knockout Inhibits Mitophagy in OMSCs AMPK is a heterotrimeric complex in which the α subunit serves as the catalytic component. In mammals, two α‐isoforms, α1 and α2, are encoded by different genes with disparate tissue distribution []. Therefore, the expression profile of α isoforms of AMPK in OMSCs was first assessed. qRT‐PCR showed that α1 was the dominant isoform, which was down‐expressed upon AFF4 deletion in OMSCs (Figure ). Thr172 phosphorylation in the kinase domain of the α subunit causes significant functional activation of AMPK and is commonly used as a marker of its activated form []. WB analysis showed that both p‐AMPK (Thr172) and total AMPK protein levels were decreased in Aff4‐KO OMSCs, whereas the expression of PINK1 and Parkin remained unchanged compared to WT cells (Figure ). Aff4‐KO OMSCs also exhibited reduced LC3B‐II level alongside elevated TOMM20 and SQSTM1/p62. Following CQ treatment to block lysosomal degradation, the LC3‐II/I ratio increased in WT cells, accompanied by TOMM20 accumulation; however, in Aff4‐KO cells, the LC3‐II/I ratio showed only a modest increase without a concomitant change in TOMM20 (Figure ). These findings confirm that AFF4 deficiency suppresses both basal mitophagy and mitophagic flux in OMSCs. Previous studies have revealed that Parkin translocation is regulated by AMPK [, , ]. Given that Aff4 loss downregulates AMPK expression without altering PINK1 and Parkin, we next examined whether Aff4 deficiency affects Parkin mitochondrial recruitment by immunofluorescence co‐localization. IF staining showed that Aff4‐KO OMSCs exhibited less overlapping fluorescent signals between Parkin and mitochondria (Figure ). Meanwhile, reduced LC3B fluorescent puncta and decreased colocalization of LC3B with mitochondria were evident in Aff4‐KO OMSCs compared to WT cells (Figure ). Although autophagosomes (bilayer membrane‐bounded vesicles) were detected in both WT and KO OMSCs by transmission electron microscopy upon CCCP induction, mitophagosomes (mitochondria containing autophagosomes) were barely observed in KO OMSCs (Figure ). Mitophagy culminates with mitophagosome‐lysosome fusion and final degradation []. The fusion event was visualized by live‐cell imaging using LysoTracker Red and MitoTracker Green. Confocal microscopy demonstrated that fewer merged (yellow) signals were detected in Aff4‐KO OMSCs (Figure ). Given the essential role of mitophagy in mitochondrial homeostasis, we also assessed the effect of AFF4 deficiency on mitochondrial status. Confocal microscopy revealed that Aff4‐KO OMSCs, in contrast to WT OMSCs, displayed extensive mitochondrial fragmentation and marked collapse of mitochondrial membrane potential (Figure ). Notably, both mitochondrial superoxide and cellular ROS showed significant accumulation in Aff4‐KO OMSCs, suggesting that defective mitophagy compromises the clearance of dysfunctional mitochondria, which further leads to gross ROS accumulation and subsequent cellular dysfunction (Figure ). Mitochondrial fusion and fission, as integral components of mitochondrial homeostasis, are closely linked to mitophagy []. We therefore examined the protein levels of key mitochondrial fusion and fission markers and found no significant differences between Aff4‐KO and WT OMSCs (Figure ). Collectively, these data indicate that defective mitophagy in Aff4‐KO OMSCs is attributable to failure to recruit the autophagic machinery, rather than to aberrant mitochondrial dynamics. Taken together, our findings support that AFF4 loss inhibits AMPK expression and mitophagy in OMSCs. Mitophagy inhibition is evidenced by decreased Parkin translocation, as well as reduced co‐localization of both LC3B and lysosomes with mitochondria. AMPK Activation Rescues Mitophagy and Osteogenesis of Aff4 Knockout OMSCs To determine whether AMPK mediates the effect of AFF4 on mitophagy and osteogenesis, AMPK agonist AICAR was first applied to reactivate AMPK signalling in Aff4‐KO OMSCs. IF assays showed that AICAR treatment promoted the mitochondrial localization of both Parkin and LC3B in Aff4‐KO OMSCs (Figure ). Consistently, AICAR upregulated the mRNA and protein levels of RUNX2, ALPL, OSX and COL1A1 (Figure ). Meanwhile, WB assays further revealed increased p‐AMPK (Thr172) and LC3B‐II/I ratio, along with decreased p62 level upon AICAR stimulation (Figure ). ALP and ARS staining suggested that AICAR treatment increased ALP activity and calcium nodule formation in Aff4‐KO OMSCs (Figure ). To verify that these effects were specifically mediated by AMPK, we treated Aff4‐KO OMSCs with the AMPK inhibitor Compound C to suppress AICAR‐induced AMPK activation. As expected, Compound C effectively abrogated AICAR‐induced rescue of mitophagy and osteogenic differentiation in Aff4‐KO OMSCs, as shown by WB analysis (Figure ). This was further corroborated by ALP and ARS staining (Figure ). In summary, AMPK signalling inhibition contributes to defective mitophagy and osteogenic differentiation of Aff4‐KO OMSCs. Disccusion Treatment of maxillofacial bone defects is challenging due to the concurrent functional and aesthetic needs. Osteogenic capacity of OMSCs, which underpins bone repair in the maxillofacial region, remains mechanistically elusive. AFF4 is known to regulate osteogenic differentiation of diverse stem cell populations. Nevertheless, its role specifically within OMSCs for maxillofacial bone regeneration remains to be elucidated. Here, the role of AFF4 in maxillofacial bone repair was first explored via a post‐extraction alveolar socket healing model. Significant upregulated AFF4 expression after tooth extraction hinted that AFF4 might be involved in alveolar socket healing. To test it, we further generated an Aff4 knockout mouse model (CAG‐iCre; Aff4 fl/fl ). Transgenic mouse line expressing Cre recombinase driven by the CAG promoter, which is both tamoxifen‐inducible and ubiquitously active, was used to circumvent the embryonic lethality of Aff4 knockout mice [, ]. Aff4 fl/fl littermates that underwent the same tamoxifen injection regimen served as WT controls, thereby excluding possible confounding influence of tamoxifen on bone metabolism []. In our study, extraction socket healing in WT mice was nearly complete by Day 21, consistent with the physiological healing process [, ], further indicating that tamoxifen administration did not adversely affect bone repair. Our in vivo results showed that postnatal inducible global Aff4 knockout led to reduced formation of new bone mass in extraction socket. Alveolar socket healing requires migration, proliferation and osteogenesis of OMSCs in the early stage, followed by osteoclast differentiation and bone remodelling []. Our further histomorphometric analysis demonstrated that, in the early healing stage, delayed socket healing upon Aff4 knockout was attributed to defective bone formation, not abnormal bone resorption. It is worth noting that osteoclastic activity during socket healing does not peak until Day 14 []. Therefore, whether AFF4 influences osteoclastic activity in the later bone remodelling stage remains to be elucidated by evaluation at later time points. Our finding aligns with the report by Dutt et al., in which aff4 loss in zebrafish led to inhibited skeletal development and bone mineralization []. Notably, Aff4 ablation did not disrupt gross body size or skeletal dimensions of mice in our study. This discrepancy may be attributed to the timing of inducible knockout in our experiment, which was after the rapid growth stage of murine skeletal development []. This approach provides a stable bone phenotype baseline, allowing us to pinpoint the role of AFF4 in skeletal homeostasis. OMSCs isolated from the mandible of Aff4 KO mice exhibited impaired osteogenic capability in vitro, corroborating the positive regulatory role of AFF4 in osteogenic fate determination of other stem cells [, , ]. AFF4 has been reported to regulate autophagic activity [], while its impact on mitophagy remains poorly understood. Mitophagy selectively degrades damaged mitochondria to guarantee mitochondrial quality control and cellular homeostasis []. Mitophagy blockade will lead to the accumulation of damaged, ROS‐generating mitochondria []. In this study, mitophagy inhibition upon Aff4 loss was validated at various mitophagy stages, spanning from initiation, progression and final degradation of the mitophagosome. Accordingly, mitochondrial dysfunction and oxidative stress in Aff4‐KO OMSCs were also observed. Mitophagy affects osteogenic activity via manipulating fate and function of osteoblastic lineage cells. Under chronic inflammatory conditions, accumulation of damaged mitochondria due to mitophagy inhibition impairs osteogenesis of hPDLSCs []. Mitophagy is also reported to prevent apoptosis, promote proliferation and osteogenesis of osteoblasts [, , ]. Mitophagy ensures the normal bioenergetic function of mitochondria, thereby meeting heightened ATP requirements during physiological osteogenesis. Moreover, mitophagy is also found to deliver amorphous calcium phosphate accumulated in mitochondria of osteoblastic lineage cells into extracellular collagen matrix, thus contributing to biomineralization process []. However, another study proposed the negative correlation between mitophagy and osteogenic potential of osteoblasts in type 2 diabetes osteoporosis []. Divergent findings on the role of mitophagy in bone formation may arise from context‐dependent variations in basal mitophagy levels and functional preferences. Consequently, the net effect of mitophagy on osteogenesis should be interpreted on a context‐specific basis. In our study, Aff4 knockout compromised osteogenesis and mitophagy, and downregulated AMPK expression in OMSCs. Given the established roles of AMPK in bone metabolism and mitophagy [, ], we employed the pharmacological modulators AICAR (agonist) and Compound C (inhibitor) to investigate whether AMPK signalling is involved in the compromised mitophagic and osteogenic capacity of Aff4‐KO OMSCs. Compound C treatment suppressed osteogenesis to an even greater extent than that observed in DMSO‐treated Aff4‐KO OMSCs. This effect may be partly attributable to the known off‐target inhibition of BMP signalling by Compound C []. Given this limitation, complementary genetic approaches, such as AMPK overexpression or siRNA‐mediated knockdown, will be required to unequivocally define the specific contribution of AMPK in future studies. In conclusion, our study reveals that alveolar bone injury stimulates AFF4 expression, which then regulates osteogenic differentiation of OMSCs and alveolar bone repair. Dysfunctional AMPK‐mitophagy under the condition of AFF4 loss contributes to the compromised osteogenic activity of OMSCs (Figure ). Overall, our investigation provides deeper insights into the function of AFF4 in bone biology and may offer clues for developing therapeutic strategies to promote maxillofacial bone regeneration. Two major limitations of this study should be acknowledged. One is that global inducible Aff4 knockout may perturb the bone microenvironment in which OMSCs reside, thereby disrupting the intricate interplay among stem cells, immune cells and local signalling molecules. Future studies using conditional knockout mouse models targeting the osteoblastic lineage (e.g., Prrx1‐Cre; Aff4 fl/fl and Osx‐Cre; Aff4 fl/fl ) would help to validate the specific contribution of OMSCs. Another limitation is that we did not further clarify the specific molecular mechanisms underlying AMPK regulation of mitophagy under AFF4‐deficient conditions. Beyond canonical Parkin‐dependent mitophagy, AMPK is found to inhibit NIX‐dependent mitophagy, which targets functioning mitochondria []. Future investigations are warranted to delineate whether and how diverse mitophagy pathways are involved in AFF4‐regulated AMPK signalling. Ethics Statement All experimental procedures were reviewed and approved by the Ethics Committee of the West China College of Stomatology (WCHSIRB‐AT‐2025‐543).